Marc Beer is an expert corporate executive having more than 25 years of development and commercialization experience in the fields of biotechnology, diagnostic, device, pharmaceutical sectors. Marc Beer is the co-founder, chairman and chief executive officer of Renovia Incorporation. The other founders include Yolanda Lorie, Ramon Iglesias and MD who is also the chief medical officer. Renovia Inc. was founded by them in 2016 and a successful closure of Series A financing through top healthcare venture capital funds. Marc Beer is also the Chief Executive Officer and Chairman of Renovia Inc. Back in 2000, Marc Beer took the office of CEO at ViaCell i.e. a biotechnology company engaged in the development, conservation and gathering of blood stem cells of the umbilical cord. ViaCell grew from a few to more than 300 employees, became public in 2005 under Marc Beer’s Supervision.
Moreover, Good Start Genetics Compensation Committees Board of Directors’ founding chairman is Marc Beer. Marc has served another Committee as a founding chairman and member of Minerva Neurosciences Incorporation Audit Committee (MNIAC). In addition to this, Marc is also the member of Graduate Studies Research (GSR) at Notre Dame and Business Advisory Council (BAC) at Miami University. During his tenure at ViaCell, Marc rendered services of Director to a publicly traded biopharmaceutical company named as Erytech Pharma. Before Marc’s employment to ViaCell, Marc Beer held different offices at Genzyme, such as, Vice president of Global Marketing. Being the VP Global Marketing his duty included commercial launch of various products which were used to cure rare disease populations at a global level.
Furthermore, being the CEO of Renovia Inc., Marc has a vision to launch new products for pelvic disorders right after the closure of Series B worth $32 million along with $10 million in the venture debt. Renovia Inc., is making numerous diagnostic and therapeutic products to serve disorders related to pelvic floor, such as, urinary incontinence. Urinary incontinence is a disorder on which researchers forecast that it affects 250 million women globally. Renovia got investment from a healthcare-centered investing firm i.e. The Longwood Fund. It also joined the Series B round with Renovia. The funds from Longwood were to use for development and testing further four diagnostic and therapeutic products in which Leva’s (product of Renovia) new generation was also included.
Marc Beer showed his gratification and enthusiasm on getting the support of The Longwood Fund in treating and improving the lives of millions of women undergoing this deadly disease of pelvic floor. He also said that collaboration with this healthcare-oriented group of investors will help to integrate their innovative and proprietary sensor technologies ultimately leading to the provision of valuable data to their customers. This valuable data includes the information of new treatment options, better understanding of pelvic floor disorders and lowering the long term healthcare expenses. Learn more: https://www.slideshare.net/MarcBeer